Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor‐1 in human breast cancer cell lines
The invasive potential of tumor cells is usually tested either by in vitro invasion assays which evaluate cell spreading ability in basement membrane‐like matrices or by in vivo invasion assays in nude mice. Both methods are laborious and time‐consuming. Tumor invasiveness is accompanied by the changes in expression of various genes. The invasive behavior of cells is therefore represented by certain gene expression patterns. The purpose of this study was to investigate whether expression patterns of several genes are characteristic for the invasiveness of cultured cells. We examined the mRNA levels of estrogen receptor (ER), progesterone receptor (PR), estrogen inducible pS2 and plasminogen activator inhibitor‐1 (PAI‐1) in 23 cell lines derived from benign and malignant breast tissues using a competitive reverse transcription‐polymerase chain reaction (cRT‐PCR) system. We also evaluated the invasiveness of these cell lines by their ability to penetrate into a collagen‐fibroblast matrix. We demonstrate that the gene expression pattern of breast cell lines is clearly associated with its in vitro invasiveness. In general, cells with ER, PR, pS2 but no PAI‐1 expression showed a non‐invasive phenotype, while cells expressing PAI‐1 mRNA but not ER mRNA are invasive. Our study indicates that the invasiveness of breast cancer cell lines is characterized by PAI‐1 gene expression and the lack of ER mRNA. This suggests that PAI‐1 may participate in the invasive process.
Unable to display preview. Download preview PDF.
- 2.Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 30: 5–11, 1994Google Scholar
- 3.Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjöld B: The South-East Sweden Breast Cancer Group. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. Int J Cancer 51: 28–33, 1992PubMedGoogle Scholar
- 6.McGuire WL: Hormone receptor in breast cancer. In: Bulbrook RD (ed) Cancer Surveys. Vol 5. Oxford University Press, Oxford, 1986, pp 527–536Google Scholar
- 17.Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513–2521, 1993PubMedGoogle Scholar
- 21.Kury FD, Schneeberger C, Sliutz G, Kubista E, Salzer H, Medl M, Leodolter S, Swoboda H, Zeillinger R, Spona J: Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. Oncogene 5: 1403–1408, 1990PubMedGoogle Scholar
- 23.Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534–544, 1992PubMedGoogle Scholar
- 28.Dong G, Schulick AH, DeYoung MB, Dichek DA: Identi-fication of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-b1 responsiveness in endothelium in vivo. JBiol Chem 271: 29969–29977, 1996Google Scholar
- 32.Knabbe C, Zugmaier G, Schmahl M, Dietel M, Lippman ME, Dickson RB: Induction of transforming growth factor-beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 14 (Suppl 2): S15–S20, 1991Google Scholar